Celgene's β-thalassemia blockbuster luspatercept nears finish line

Celgene's luspatercept is on track for a dual approval after FDA on Tuesday accepted a BLA for the therapy to treat β-thalassemia and

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE